share_log

Lilly Reveals Details Of Presentations At ASCO Annual Meeting

Benzinga ·  May 24 05:35

Eli Lilly said data from studies of Verzenio (abemaciclib; a CDK4/6 inhibitor), Retevmo (selpercatinib; a rearranged during transfection [RET] inhibitor), olomorasib (an investigational KRAS G12C inhibitor) and imlunestrant (an investigational oral selective estrogen receptor degrader [SERD]) will be presented at the meeting.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment